Sarah Duncan Purchases 34,127 Shares of NIOX Group (LON:NIOX) Stock

NIOX Group Plc (LON:NIOX) insider Sarah Duncan purchased 34,127 shares of the business’s stock in a transaction that occurred on Friday, May 29th. The shares were purchased at an average cost of GBX 59 per share, with a total value of £20,134.93.

Sarah Duncan also recently made the following trade(s):

• On Thursday, May 28th, Sarah Duncan purchased 34,139 shares of NIOX Group stock. The shares were purchased at an average cost of GBX 58 per share, with a total value of £19,800.62.
• On Thursday, May 28th, Sarah Duncan sold 34,219 shares of NIOX Group stock. The stock was sold at an average price of GBX 58, for a total transaction of £19,847.02.
• On Friday, May 29th, Sarah Duncan sold 33,916 shares of NIOX Group stock. The stock was sold at an average price of GBX 59, for a total transaction of £20,010.44.
• On Thursday, April 16th, Sarah Duncan sold 164,612 shares of NIOX Group stock. The stock was sold at an average price of GBX 56, for a total transaction of £92,182.72.

NIOX Group Stock Performance

LON NIOX traded up GBX 0.14 during trading hours on Friday, hitting GBX 58.54. 268,082 shares of the stock were exchanged, compared to its average volume of 836,268. The company has a market cap of £246.11 million, a price-to-earnings ratio of 35.69 and a beta of 0.92. NIOX Group Plc has a 12-month low of GBX 53.84 and a 12-month high of GBX 77.60. The stock has a 50-day moving average of GBX 60.09 and a 200 day moving average of GBX 64.66. The company has a quick ratio of 1.94, a current ratio of 3.81 and a debt-to-equity ratio of 1.36.

NIOX Group (LON:NIOX) last posted its quarterly earnings results on Tuesday, March 24th. The company reported GBX 4.03 earnings per share (EPS) for the quarter. NIOX Group had a net margin of 14.37% and a return on equity of 10.14%. As a group, equities research analysts forecast that NIOX Group Plc will post 1.1658256 earnings per share for the current year.

About NIOX Group

NIOX Group plc is a medical technology company focused on improving the lives of millions of people suffering from respiratory health issues globally. NIOX develops and markets innovative, non-invasive diagnostic products for chronic airway diseases, primarily asthma and COPD. Its lead product, NIOX VERO®, enables the accurate measurement of fractional exhaled nitric oxide (FeNO), an established biomarker for airway inflammation, supporting better diagnosis, monitoring and management of asthma and COPD in clinical and research settings.

Headquartered in the UK and listed on the London Stock Exchange (ticker: NIOX), the company operates internationally, serving healthcare professionals in over 50 countries.